
PR02  The co-expression of VISTA and TIGIT on cytotoxic T cells defines subpopulation with altered immunometabolism.  Cassandra Gilmour, Cleveland Clinic Foundation, Cleveland, OH, United States.

PR06  Reprogramming of naïve B cells in pancreatic cancer subverts humoral immunity.  Yuliya Pylayeva-Gupta, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

PR08  Context is everything: Microbiota-specific T follicular helper cells in colorectal cancer.  Abigail E. Overacre-Delgoffe, University of Pittsburgh, Pittsburgh, PA, United States.

PR09  Macrophage promotion of anti-androgen resistance in prostate cancer bone disease.  Bin-Zhi Qian, MRC Centre for Reproductive Health, College of Medicine and Veterinary Medicine,The University of Edinburgh, Edinburgh, UK, Edinburgh, United Kingdom.

PR10  Inhibition of MEK1/2 overcomes resistance to αPD-1 blockade in pancreatic ductal adenocarcinoma through modulation of NETosis in tumor-associated neutrophils.  Brian Herbst, Johns Hopkins University School of Medicine, Baltimore, MD, United States.